论文部分内容阅读
缺血修饰白蛋白(ischemia-modified albumin,IMA)是近年广受关注的心肌缺血早期诊断指标。它的生成是由于缺血发作时人血清白蛋白氨基酸末端序列乙酰化或缺失所致,IMA是迄今为止唯一经美国FDA批准上市销售用为临床诊断的心肌缺血生化标志物。缺血修饰白蛋白敏感性极高,对心肌缺血的早期诊断及预后均有很高的临床价值。但近年的大量研究发现其诊断心肌缺血的特异性较低,使其在临床的应用受到局限。本文作者就缺血修饰白蛋白临床研究现状作一综述,为其进一步的临床应用助益。
Ischemia-modified albumin (IMA) is an early diagnosis of myocardial ischemia in recent years. Its production is due to the acetylation or deletion of human serum albumin amino acid sequence during ischemic attack. IMA is by far the only myocardial ischemia biochemical marker for clinical diagnosis approved by the FDA for sale. Ischemia-modified albumin is highly sensitive and has high clinical value for the early diagnosis and prognosis of myocardial ischemia. But in recent years a large number of studies found that the specificity of its diagnosis of myocardial ischemia is low, so that its clinical application is limited. The author of this review summarizes the current status of the clinical research on ischemia-modified albumin, which is helpful for further clinical application.